Author: Busani, Stefano; Roat, Erika; Tosi, Martina; Biagioni, Emanuela; Coloretti, Irene; Meschiari, Marianna; Gelmini, Roberta; Brugioni, Lucio; De Biasi, Sara; Girardis, Massimo
Title: Adjunctive Immunotherapy With Polyclonal Ig-M Enriched Immunoglobulins for Septic Shock: From Bench to Bedside. The Rationale for a Personalized Treatment Protocol Cord-id: yi2cqys7 Document date: 2021_2_18
ID: yi2cqys7
Snippet: Septic shock still has a high mortality rate which has not hinted at decreasing in recent years. Unfortunately, randomized trials failed mainly because the septic patient was considered as a homogeneous entity. All this creates a sort of therapeutic impotence in everyday clinical practice in treating patients with septic shock. The need to customize therapy on each patient with sepsis has now become an established necessity. In this scenario, adjuvant therapies can help if interpreted as modulat
Document: Septic shock still has a high mortality rate which has not hinted at decreasing in recent years. Unfortunately, randomized trials failed mainly because the septic patient was considered as a homogeneous entity. All this creates a sort of therapeutic impotence in everyday clinical practice in treating patients with septic shock. The need to customize therapy on each patient with sepsis has now become an established necessity. In this scenario, adjuvant therapies can help if interpreted as modulators of the immune system. Indeed, the host's immune response differs from patient to patient based on the virulence of the pathogen, comorbidity, infection site, and prolonged hospitalization. In this review, we summarize the rationale for using immunoglobulins as an adjunctive treatment. Furthermore, we would like to suggest a possible protocol to personalize treatment in the different clinical scenarios of the host's response to serious infectious events.
Search related documents:
Co phrase search for related documents- abdominal surgery and acute renal failure: 1
- absolute contraindication and adjuvant therapy: 1
- action mechanism and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- action mechanism and adaptive immune system: 1
- action mechanism and additional therapy: 1
- action mechanism and adequate power: 1
- action mechanism and adjunctive therapy: 1, 2
- action mechanism and adjunctive treatment: 1
- action mechanism and adjuvant therapy: 1, 2, 3, 4
- acute lung injury and adaptive immune system: 1, 2, 3
- acute lung injury and adjunctive therapy: 1, 2, 3
- acute lung injury and adjunctive treatment: 1, 2, 3, 4, 5
- acute lung injury and adjuvant therapy: 1, 2, 3, 4
- acute renal failure and adjunctive therapy: 1, 2
- acute renal failure and adjuvant therapy: 1
- adaptive immune system and adjunctive treatment: 1
- adaptive immune system and adjuvant therapy: 1
- additional therapy and adjunctive treatment: 1
- additional therapy and adjuvant therapy: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date